- $488.07m
- $320.48m
- $10.84m
Brief: Crescent Biopharma Inc Q2 EPS $-4.93
Crescent Biopharma Inc expected to post a loss of $1.76 a share - Earnings Preview
Brief: Crescent Biopharma Appoints Jan Pinkas, Ph.D., As Chief Scientific Officer
Brief: GlycoMimetics Stockholders Approve Proposed Merger With Crescent Biopharma And All Related Proposals
GlycoMimetics Inc reports results for the quarter ended March 31 - Earnings Summary
GlycoMimetics Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: GlycoMimetics Says Following Termination, Co Will Not Have Any Material Financial Or Other Obligations Under Agreement
Brief: Glycomimetics Inc Says CEO Harout Semerjian And CFO Brian Hahn To Step Down
Brief: GlycoMimetics On Dec 19 Nasdaq Grants Glycomimetics 180 Days To Regain Compliance
Brief: Glycomimetics Enters Into Acquisition Agreement With Crescent Biopharma
Brief: GlycoMimetics Announces Strategic Review, Restructuring Plan
Brief: Glycomimetics Inc -On June 21, Got Notice From Nasdaq, Co Is Not In Compliance With Nasdaq’S Listing Rule 5450(A)(1)
GlycoMimetics Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- ServiceNow, Ulta Beauty, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-GoDaddy, Walt Disney, Aerovironment
U.S. STOCKS ON THE MOVE-NAPCO Security Technologies, Outset Medical, US energy sector
GlycoMimetics hits record low as blood cancer drug fails in late-stage study
U.S. STOCKS ON THE MOVE-U.S. Steel, Freshpet, oil stocks
U.S. STOCKS ON THE MOVE-Paramount, Occidental Petroleum, Perficient